Close Menu
Home › Lower Cutoff Score for Oncotype DX Test May Be Needed for Male Breast Cancer Patients

Lower Cutoff Score for Oncotype DX Test May Be Needed for Male Breast Cancer Patients

Nov 20, 2019
|
staff reporter

NEW YORK – Recurrence scores from Genomic Health's Oncotype DX test might have a different meaning for men with breast cancer, suggesting a need for a lower cutoff score to predict mortality among male patients, a new study has found.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
11
Featured Webinar

Advances in Precision Oncology: Tertiary Analysis Software for Solid Tumor NGS

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. Roche Ending Partnership With Syapse

  2. NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

  3. FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

  4. Polygenic Modifiers of Pathogenic Genes May Refine Disease Risk Prediction

    Premium

  5. PGDx Gets IDE For Tissue NGS Test in Merck Immunotherapy Trial

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.